Successful Management of Generalized Myasthenia Gravis Induced by Atezolizumab in a Patient With Extensive-Stage SCLC: A Case Report

Immune checkpoint inhibitors including atezolizumab and durvalumab have been approved as the first-line treatment in extensive-stage SCLC. However, immune checkpoint inhibitors can cause immune-related adverse events, which will lead to the shelving of follow-up treatment and the progression and det...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shuang, Shi, Jiayu, Guan, Yuzhou, Zhang, Li, Wang, Hanping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563168/
https://www.ncbi.nlm.nih.gov/pubmed/36246044
http://dx.doi.org/10.1016/j.jtocrr.2022.100354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563168/
https://www.ncbi.nlm.nih.gov/pubmed/36246044
http://dx.doi.org/10.1016/j.jtocrr.2022.100354

Ejemplares similares